
A stabilised GHRH(1-44) analogue for laboratory studies of the somatotropic axis and GHRH-receptor signalling.
- 1 × sealed pre-filled multi-dose research pen
- Batch / lot label with Certificate of Analysis reference
- Tamper-evident verification seal
Body Pharm Tesamorelin 32mg
Official Body Pharm store — genuine, batch-tested stock
Tesamorelin 32 mg supplied as a pre-filled multi-dose research pen. Tesamorelin is a synthetic growth-hormone-releasing hormone (GHRH) analogue used in laboratory studies of the somatotropic axis. Supplied strictly for laboratory research. Not for human or veterinary use.
Research use only. For laboratory research use only. Not for human or veterinary use, diagnosis, treatment or any clinical application. This product is not a medicine, food, dietary supplement or cosmetic, and no medical, therapeutic or performance claims are made or implied. Read our research-use policy.
- HPLC-tested batch with published Certificate of Analysis
- Sealed, tamper-evident laboratory pack
- Tracked UK dispatch in plain outer packaging
Specification
- Declared quantity
- 32 mg
- CAS
- 218949-48-5
- Molecular formula
- C221H366N72O67S
- Format
- Pre-filled multi-dose research pen (solution)
- HPLC purity (batch)
- 98.10% · batch TS327745
- Storage
- Store refrigerated at 2–8 °C. Protect from light. Do not freeze.
- Intended use
- Laboratory research use only
Overview
Body Pharm Tesamorelin 32 mg is a sealed, pre-filled multi-dose research pen containing 32 mg of tesamorelin in solution. Tesamorelin is a synthetic 44-amino-acid analogue of human growth-hormone-releasing hormone (GHRH 1-44) carrying an N-terminal trans-3-hexenoyl modification that stabilises the peptide against dipeptidyl-peptidase cleavage.
The pen is a laboratory research material. It is supplied strictly for laboratory research and is not for human or veterinary use. It is not a medicine, food, dietary supplement or cosmetic, and no medical, therapeutic or performance claims are made or implied. No dosing information is provided.
Research background
Tesamorelin acts at the GHRH receptor on pituitary somatotrophs. In the laboratory it is used as a stabilised, full-length GHRH-receptor agonist in studies of the hypothalamic–pituitary–somatotropic axis, GHRH-receptor signalling and downstream IGF-1 axis biology [1][2]. It sits alongside CJC-1295 (a truncated GHRH 1-29 analogue) as a GHRH-receptor ligand, and upstream of recombinant somatropin, which acts at the growth-hormone receptor directly. See our CJC-1295 vs Ipamorelin guide for how the GH-axis compounds relate.
Specification
- Compound: Tesamorelin (trans-3-hexenoyl-GHRH 1-44 amide)
- Declared quantity: 32 mg per pen
- CAS: 218949-48-5
- Molecular formula: C221H366N72O67S
- Format: Solution, pre-filled multi-dose research pen
Quality documentation
Every batch is HPLC-tested for purity and identity. The batch-specific Certificate of Analysis is published on this page and on our Certificates of Analysis page, and the batch number is printed on the pen label.
Storage and handling
Store refrigerated at 2–8 °C. Protect from light. Do not freeze. Handle only with appropriate personal protective equipment in a laboratory setting and dispose of the pen as laboratory sharps waste. Keep out of reach of children and animals.
Availability
Tesamorelin 32 mg is currently on the waitlist. Registering your interest takes no payment; we notify you by email when the next batch is released.
Frequently Asked Questions
Is Tesamorelin 32mg for human use?
No. It is supplied strictly for laboratory research and is not for human or veterinary use. No dosing or administration information is provided.
How does tesamorelin differ from CJC-1295?
Both are GHRH-receptor agonists. Tesamorelin is a stabilised full-length GHRH(1-44) analogue; CJC-1295 (no DAC) is a truncated GHRH(1-29) analogue with four stabilising amino-acid substitutions.
How is purity verified?
Each batch is HPLC-tested for purity and identity; the Certificate of Analysis for that batch is published on this page.
References
- Ferdinandi ES, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007. pubmed.ncbi.nlm.nih.gov/17214611
- PubChem compound summary: Tesamorelin. pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin


